A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 610 participants.

Also called NCT01178073

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 610 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01178073
Other papers using this trial's data
  • Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension Respiratory research, 2019-09-12 DOI, PubMed 31511080, PMC6739949 In the PMC Open Access subset under CC BY.
  • Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension The New England journal of medicine, 2015-08-27 DOI, PubMed 26308684
  • Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis Annals of the rheumatic diseases, 2020-05 DOI, PubMed 32161055, PMC7213337 PubMed links an erratum for this paper. Erratum: PMID 32816781 In the PMC Open Access subset under CC BY-NC.
  • Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial Annals of the rheumatic diseases, 2017-07 DOI, PubMed 28039187, PMC5530350 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01178073. Randomized; quadruple masking; primary purpose treatment. Start 2010-10-01 (registry gives no type); primary completion 2014-07-31 (actual). Results posted on 2015-04-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Acronym
AMBITION
Condition
Hypertension, Pulmonary
Intervention (Drug)
ambrisentan
Intervention (Drug)
tadalafil
Lead sponsor
GlaxoSmithKline (class: industry)
Collaborator
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct01178073
Content hash
53e5525d293390b11894665867e954f3c588f30a3ce3876fb6f47f23bf8ba7f3